3BP1 Inhibitors
The chemical class designated as 3BP1 inhibitors comprises a strategic selection of compounds meticulously chosen to modulate the expression and function of 3BP1. Dasatinib, Bosutinib, and Imatinib are BCR-ABL tyrosine kinase inhibitors that impact the Src family kinases. By inhibiting BCR-ABL, these compounds indirectly modulate 3BP1 through the Src signaling pathway, ensuring precise control over the Src pathway and influencing 3BP1 expression and function. Src family kinase inhibitors such as Saracatinib, PP2, WH-4-023, PP1, KX2-391, A-419259, and WHI-P131 directly target the Src signaling pathway. By inhibiting Src, these compounds precisely modulate 3BP1 through the Src pathway, showcasing a nuanced approach to controlling the signaling cascade and influencing 3BP1 expression and function.
Furthermore, KU-0059436 and GDC-0941, as dual mTOR and PI3K or selective PI3K inhibitors, respectively, impact the PI3K-Akt signaling pathway. By inhibiting PI3K, these compounds indirectly modulate 3BP1 through the PI3K-Akt pathway, providing a comprehensive approach to influencing 3BP1 expression and function. In conclusion, the 3BP1 inhibitors chemical class presents a comprehensive toolkit for the precise modulation of 3BP1 expression and function through targeted interference with the Src and PI3K-Akt signaling pathways. Each compound within this class exerts its influence through specific biochemical or cellular pathways, showcasing the intricacies of cellular signaling networks and providing valuable tools for the scientific exploration of 3BP1 function.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a BCR-ABL tyrosine kinase inhibitor impacting the Src family kinases. By inhibiting BCR-ABL, Dasatinib indirectly modulates 3BP1 through the Src signaling pathway. The compound's specificity for BCR-ABL ensures precise control over the Src pathway, subsequently influencing 3BP1 expression and function. | ||||||
Saracatinib | 379231-04-6 | sc-364607 sc-364607A | 10 mg 200 mg | $115.00 $1056.00 | 7 | |
Saracatinib is a Src family kinase inhibitor impacting the Src signaling pathway. By inhibiting Src, Saracatinib indirectly modulates 3BP1 through the Src pathway. The compound's specificity for Src ensures precise control over the signaling pathway, subsequently influencing 3BP1 expression and function. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a Src family kinase inhibitor targeting the Src signaling pathway. By inhibiting Src, PP2 indirectly modulates 3BP1 through the Src pathway. The compound's specificity for Src ensures precise control over the signaling pathway, subsequently influencing 3BP1 expression and function. | ||||||
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $45.00 $111.00 | 61 | |
Imatinib is a BCR-ABL tyrosine kinase inhibitor impacting the Src family kinases. By inhibiting BCR-ABL, Imatinib indirectly modulates 3BP1 through the Src signaling pathway. The compound's specificity for BCR-ABL ensures precise control over the Src pathway, subsequently influencing 3BP1 expression and function. | ||||||
WH-4-023 | 837422-57-8 | sc-507457 | 10 mg | $172.00 | ||
WH-4-023 is a Src family kinase inhibitor affecting the Src signaling pathway. By inhibiting Src, WH-4-023 indirectly modulates 3BP1 through the Src pathway. The compound's specificity for Src ensures precise control over the signaling pathway, subsequently influencing 3BP1 expression and function. | ||||||
PP 1 | 172889-26-8 | sc-203212 sc-203212A | 1 mg 5 mg | $86.00 $145.00 | 6 | |
PP1 is a Src family kinase inhibitor impacting the Src signaling pathway. By inhibiting Src, PP1 indirectly modulates 3BP1 through the Src pathway. The compound's specificity for Src ensures precise control over the signaling pathway, subsequently influencing 3BP1 expression and function. | ||||||
KX2-391 | 897016-82-9 | sc-364520 sc-364520A | 5 mg 50 mg | $180.00 $1140.00 | ||
KX2-391 is a Src kinase inhibitor affecting the Src signaling pathway. By inhibiting Src, KX2-391 indirectly modulates 3BP1 through the Src pathway. The compound's specificity for Src ensures precise control over the signaling pathway, subsequently influencing 3BP1 expression and function. | ||||||
A 419259 trihydrochloride | 1435934-25-0 | sc-361094 | 5 mg | $213.00 | 6 | |
A-419259 is a Src family kinase inhibitor impacting the Src signaling pathway. By inhibiting Src, A-419259 indirectly modulates 3BP1 through the Src pathway. The compound's specificity for Src ensures precise control over the signaling pathway, subsequently influencing 3BP1 expression and function. | ||||||
Janex-1 | 202475-60-3 | sc-205354 sc-205354A | 1 mg 5 mg | $36.00 $153.00 | 1 | |
Janex-1 is a Src family kinase inhibitor affecting the Src signaling pathway. By inhibiting Src, WHI-P131 indirectly modulates 3BP1 through the Src pathway. The compound's specificity for Src ensures precise control over the signaling pathway, subsequently influencing 3BP1 expression and function. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
KU-0059436 is a dual mTOR and PI3K inhibitor impacting the PI3K-Akt signaling pathway. By inhibiting PI3K, KU-0059436 indirectly modulates 3BP1 through the PI3K-Akt pathway. The compound's dual specificity ensures comprehensive control over the signaling pathway, subsequently influencing 3BP1 expression and function. | ||||||